US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kurv Yield Premium Strategy Tesla (TSLA) ETF

19.95

+0.67003.48%

Post-market: 19.950.00000.00%17:42 EDT

Volume:62.34K

Turnover:1.24M

Market Cap:20.55M

PE:- -

High:20.27

Open:19.61

Low:19.61

Close:19.28

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

Press Release: Harbour BioMed Reports Full Year 2024 Financial Results

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TSLP"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TSLP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TSLP\",,,,,undefined,":{"symbol":"TSLP","market":"US","secType":"STK","nameCN":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","latestPrice":19.95,"timestamp":1746820800000,"preClose":19.28,"halted":0,"volume":62340,"hourTrading":{"tag":"盘后","latestPrice":19.95,"preClose":19.95,"latestTime":"17:42 EDT","volume":22,"amount":444.2875,"timestamp":1746826945059},"delay":0,"floatShares":1030000,"shares":1030000,"eps":0,"marketStatus":"Market Closed","change":0.67,"latestTime":"05-09 16:00:00 EDT","open":19.61,"high":20.2678,"low":19.61,"amount":1243938.9741,"amplitude":0.034118,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"exchange":"AMEX","adjPreClose":19.28,"sharesOutstanding":1030000,"nav":19.33,"aum":19909900,"dividendRate":0.445614,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":19.55,"preClose":19.28,"latestTime":"08:30 EDT","volume":52,"amount":1018.600076,"timestamp":1746793848244},"postHourTrading":{"tag":"盘后","latestPrice":19.95,"preClose":19.95,"latestTime":"17:42 EDT","volume":22,"amount":444.2875,"timestamp":1746826945059},"volumeRatio":1.802526,"impliedVol":0.418,"impliedVolPercentile":0.8},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TSLP\",,,,,undefined,":{"symbol":"TSLP","floatShares":1030000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.802526,"shares":1030000,"dividePrice":8.89,"high":20.2678,"amplitude":0.034118,"preClose":19.28,"low":19.61,"week52Low":15.36,"pbRate":"--","week52High":34.2895,"institutionHeld":0,"latestPrice":19.95,"eps":0,"divideRate":0.445614,"volume":62340,"delay":0,"ttmEps":0,"open":19.61,"prevYearClose":30.27,"prevWeekClose":19.9339,"prevMonthClose":19.63,"prevQuarterClose":18.48,"fiveDayClose":19.9339,"twentyDayClose":17.53,"sixtyDayClose":24.54},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TSLP\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TSLP\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532683802","title":"AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2532683802","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532683802?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:01","pubTimestamp":1746129660,"startTime":"0","endTime":"0","summary":"THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen  today announced financial results for the first quarter of 2025.\"Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects,\" said Robert A. Bradway, chairman and chief executive officer.For the first quarter, total revenues increased 9% to $8.1 billion in comparison to the first quarter of 2024.Product sales grew 11%, primarily driven by 14% volume growth, partially offset by 6% lower net selling price. U.S. sales grew 14%.Fourteen products delivered at least double-digit sales growth in the first quarter, includingRepatha , BLINCYTO , TEZSPIRE , EVENITY , TAVNEOS  and UPLIZNA .Non-GAAP EPS increased 24% from $3.96 to $4.90, driven by higher revenues, partially offset by higher operating expenses.Repatha  sales increased 27% year-over-year to $656 million in the first quarter, pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2025-200100246.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2025-200100246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2468319806.SGD","LU1057294990.SGD","SLE","IE0009355771.USD","LU0122379950.USD","LU2242652126.USD","LU0109394709.USD","GIPR","BK4160","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4188","LU2089984988.USD","BK4233","BK4585","IE00BJT1NW94.SGD","TSLP","BK4205","IE0002141913.USD","LU0058720904.USD","LU2242646821.SGD","BK4200","PN","TCS","BK4599","LU1061106388.HKD","LU0320765992.SGD","LU1023059063.AUD","SG9999001440.SGD","BK4096","BK4588","LU2112291526.USD","BK4533","LU0889565916.HKD","BK4566","MPA","MTA","IE00BFTCPJ56.SGD","BK4534","BK4139","BK4211","LU0868494617.USD","AMGN","FCF","TCI","BK4581","LU0289739699.SGD","LU1983299246.USD","BK4077"],"gpt_icon":0},{"id":"2529637228","title":"Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2529637228","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529637228?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:59","pubTimestamp":1745319540,"startTime":"0","endTime":"0","summary":"- Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 -. WAYNE, Pa, April 22, 2025  -- Aclaris Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration  has cleared its Investigational New Drug  application for a Phase 1a/1b clinical trial of ATI-052, a potential best-in-class bispecific anti-TSLP/IL-4R monoclonal antibody.ATI-052 is an investigational, potential best-in-class anti-TSLP/IL-4R bispecific monoclonal antibody being developed to treat certain immuno-inflammatory diseases. ATI-052 targets thymic stromal lymphopoietin  and interleukin-4 receptor  that blocks both the upstream TSLP receptor signal transduction and downstream IL-4R activation which inhibits both IL-4 and IL-13 signaling, thereby inhibiting this central proinflammatory pathway and potentially offering enhanced efficacy through dua","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aclaris-therapeutics-secures-u-food-105900381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z4B17.USD","ATI","IE00B7SZL793.SGD","LU2065731478.USD","TSLP","IE00B66KJ199.SGD","BK4007","IE0031619046.USD","LU1878469433.USD","BK4006","ACRS"],"gpt_icon":0},{"id":"2523191987","title":"Press Release: Harbour BioMed Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2523191987","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523191987?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:13","pubTimestamp":1743415980,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025. CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed , a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its financial results for the year ended December 31, 2024.Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed,  commented: \"The year 2024 was a pivotal period for Harbour BioMed, marked by significant progress in research and development, strategic business expansion, and operational excellence. Despite a challenging macroeconomic environment, the Company demonstrated remarkable resilience, navigating inflationary pressures, global supply chain disruptions, and geopolitical uncertainties while remaining focused on its long-term growth objectives.Compared to 2023, the company's revenue sustainability has continued to improve. Annual recurring revenue in","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","SD","TM","BK4585","03160","BK1574","02142","BK4232","BK4213","R","TSLP","BK4588","BK1583","BK1161","BK4604","BK4555","BK4099"],"gpt_icon":0},{"id":"2516635849","title":"Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516635849","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516635849?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:01","pubTimestamp":1741006860,"startTime":"0","endTime":"0","summary":"- CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing - HAMPTON, N.J., March  03, 2025  (GLOBE NEWSWIRE) -- Celldex Therapeutic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035595/24180/en/Celldex-Therapeutics-Presents-Positive-Preclinical-Data-from-Inflammatory-Bispecific-Antibody-Program-CDX-622-at-AAAAI-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139","CDX","TSLP"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TSLP\",params:#limit:5,,,undefined,":[{"date":"2025-05-07","symbol":"TSLP","amount":0.55,"announcedDate":"2025-05-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-07","defaultRemindTime":1746624600000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-08","payableDate":"2025-05-07","currency":"USD","dateTimestamp":1746590400000,"payDate":"2025-05-08"},{"date":"2025-04-02","symbol":"TSLP","amount":0.55,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-02","defaultRemindTime":1743600600000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-03","payableDate":"2025-04-02","currency":"USD","dateTimestamp":1743566400000,"payDate":"2025-04-03"},{"date":"2025-03-05","symbol":"TSLP","amount":0.7,"announcedDate":"2025-03-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-05","defaultRemindTime":1741185000000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-06","payableDate":"2025-03-05","currency":"USD","dateTimestamp":1741150800000,"payDate":"2025-03-06"},{"date":"2025-02-05","symbol":"TSLP","amount":1,"announcedDate":"2025-02-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-05","defaultRemindTime":1738765800000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-06","payableDate":"2025-02-05","currency":"USD","dateTimestamp":1738731600000,"payDate":"2025-02-06"},{"date":"2025-01-23","symbol":"TSLP","amount":1.3,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-23","defaultRemindTime":1737642600000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-24","payableDate":"2025-01-23","currency":"USD","dateTimestamp":1737608400000,"payDate":"2025-01-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TSLP\",market:\"US\",,,undefined,":[{"executeDate":"2023-11-22","recordDate":"2023-11-24","paymentDate":"2023-11-27","value":0.5775,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-22","value":0.6664,"currency":"USD"},{"executeDate":"2024-01-24","recordDate":"2024-01-25","paymentDate":"2024-01-26","value":0.5555,"currency":"USD"},{"executeDate":"2024-02-21","recordDate":"2024-02-22","paymentDate":"2024-02-23","value":0.313,"currency":"USD"},{"executeDate":"2024-03-20","recordDate":"2024-03-21","paymentDate":"2024-03-22","value":0.5189,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TSLP\",market:\"US\",delay:false,,,undefined,":{}}}